ImmuneRegen BioSciences Holdings Inc. Establishes Research Entity in Singapore Biotech Company to Test for Efficacy in Treating SARS, Avian Flu, Toxic Inhalation SCOTTSDALE, Ariz., March 29 /PRNewswire-FirstCall/ -- IR BioSciences Holdings, Inc. (BULLETIN BOARD: IRBH) , owner of biotechnology research and development company ImmuneRegen BioSciences, Inc., today announced it has established a research entity in Singapore and has created IMM BioSciences Asia, Ltd. IR BioSciences Holdings, Inc. will license the use of its proprietary compound Homspera through this new entity for studies on the compound's efficacy in potentially treating adverse effects of cancer, cigarette smoking, influenza, SARS/Avian Flu, HIV among others. The future studies are expected to be held at research labs located at Biopolis, a center for biomedical sciences located in close proximity to the National University of Singapore, University Hospital and the Singapore Science Parks. The campus currently houses many mid-size and large biotech companies, as well as several key government agencies, publicly funded research institutes and R&D labs. "We chose this facility very carefully," explains Michael K. Wilhelm, CEO of ImmuneRegen BioSciences, Inc. "This facility mirrored our needs and corporate direction. The overall design encourages strategic assistance and fosters a collaborative culture among the private and public research community, which is key in any research study. We are currently working on securing the space and should be moving ahead with our studies shortly." About ImmuneRegen BioSciences, Inc. ImmuneRegen BioSciences, Inc. is a biotechnology company engaged in the research and development of applications utilizing modified Substance P, a naturally occurring immunomodulator. Derived from homeostatic substance P, the company has named their proprietary compound "Homspera." The Company's initial focus is on the continuing development of Homspera for various applications for use in improving pulmonary function and stimulating the human immune system. For more information, please visit the Company's website at http://www.immuneregen.com/. History of Homspera ImmuneRegen's patents and continued substance P research are derived from discoveries made during research funded by the Air Force Office of Scientific Research in the early 1990s. During this research, Dr. Mark Witten (ImmuneRegen co-founder and acting head researcher) and his associates observed that the exposure of animals to jet fuels resulted in pathological changes in the lung and immune systems of those exposed. It was also observed that such exposure resulted in depletion of substance P from the lungs of the animals. These studies further showed that the administration of substance P may help prevent and reverse the effects of jet fuel exposure in the lungs, as well as protect and regenerate the immune system. The immune findings led to early research on the treatment of exposure to acute radiation and on the possible reversal of lung damage caused by ARDS and cigarette smoke. Statements about the Company's future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts, are "forward-lookingstatements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. The Company's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research collaborations, clinicaltrials and product development programs, the evaluation of potential opportunities, the level of corporate expenditures, capital market conditions, and others set forth in the Company's periodic report on Form 8-K as filed with the Securities and Exchange Commission on July 7, 2003. DATASOURCE: ImmuneRegen BioSciences, Inc. CONTACT: media, Michelle Derden of Spelling Communications, +1-310-477-9500, ; or investors, Tony Schor of InvestorAwareness, +1-847-945-2222, , both for ImmuneRegen BioSciences Holdings Inc. Web site: http://www.immuneregen.com/

Copyright